Hsp90

Introduction

Heat shock protein 90 (Hsp90) is a highly conserved molecular chaperone that plays a central role in the folding, activation, and stabilization of a wide variety of client proteins. Its activity is ATP-dependent and involves interaction with a diverse set of co‑chaperones that modulate its conformation and function. Hsp90 is ubiquitous in eukaryotes, with multiple isoforms expressed in different cellular compartments and tissues. The protein has been implicated in many cellular processes, including signal transduction, protein quality control, and stress responses, and is therefore a key factor in maintaining proteostasis.

History and Discovery

The first reports of Hsp90 emerged in the early 1970s when researchers observed an 86‑kDa protein that was strongly induced in mammalian cells after exposure to elevated temperatures. Subsequent work identified the same protein in yeast, Drosophila, and plants, confirming its evolutionary conservation. In 1982, the gene encoding the protein was cloned from HeLa cells, and the protein’s ability to bind ATP was characterized. Over the following decades, extensive studies revealed the chaperone cycle of Hsp90, its client repertoire, and the roles of its co‑chaperones. The recognition of Hsp90 as a potential drug target, particularly in oncology, accelerated in the 1990s when small‑molecule inhibitors such as geldanamycin were discovered to bind the ATP‑binding pocket and disrupt chaperone activity.

Structure and Family Members

Gene and Protein Families

The Hsp90 family is subdivided into several paralogs in eukaryotic genomes. In mammals, three main cytosolic isoforms exist: Hsp90α, Hsp90β, and a third less studied paralog, Hsp90γ. Additionally, two mitochondrial isoforms, TRAP1 and Hsp90α, and a nuclear isoform, Hsp90β, are encoded by the same genes but differ in post‑translational processing and subcellular targeting. In yeast, the sole cytosolic Hsp90 is Hsc82, while its mitochondrial counterpart is Hsp82. Plant genomes contain several isoforms, including cytosolic, chloroplast, and mitochondrial Hsp90s. The conserved sequence motifs across the family include an N‑terminal ATP‑binding domain, a middle domain responsible for client interaction, and a C‑terminal dimerization domain.

Domain Architecture

Hsp90 is a dimeric protein, each monomer comprising three distinct domains:

N‑terminal domain (NTD): Contains the ATP‑binding pocket; ATP binding induces a conformational change that initiates the chaperone cycle.
Middle domain (MD): Mediates interaction with client proteins and co‑chaperones; ATP hydrolysis occurs within this domain.
C‑terminal domain (CTD): Responsible for dimerization; also contains a short motif that binds certain co‑chaperones.

Crystallographic studies have revealed that the ATPase cycle proceeds through a series of closed and open states, regulated by conformational changes that propagate from the NTD to the CTD. The ATP hydrolysis rate is relatively slow compared to other ATPases, allowing Hsp90 to function as a stable scaffold during client maturation.

Isoforms and Splice Variants

Alternative splicing contributes to Hsp90 diversity in vertebrates. For example, the Hsp90α gene produces two splice variants differing in a 26‑amino‑acid insertion within the middle domain, which influences its interaction with specific co‑chaperones. Post‑translational modifications, including phosphorylation, acetylation, and methylation, further diversify the functional properties of Hsp90 isoforms. These modifications can modulate ATPase activity, client binding affinity, and subcellular localization.

Function and Mechanisms

Chaperone Activity

Hsp90 facilitates the maturation of client proteins by stabilizing intermediate folding states. Unlike classical chaperones that primarily prevent aggregation, Hsp90 acts as a catalyst that accelerates the final folding steps of complex, multi‑domain proteins. Many client proteins are signaling molecules, such as kinases, transcription factors, and steroid hormone receptors, whose activity depends on the proper conformation of their functional domains.

ATPase Cycle

The chaperone cycle of Hsp90 can be summarized in the following stages:

ATP binding: ATP binds to the NTD of each monomer, promoting a closed conformation.
Client engagement: Clients and co‑chaperones bind to the MD, stabilizing the closed state.
ATP hydrolysis: Hydrolysis of ATP to ADP triggers a conformational shift that releases the client in a more mature state.
ADP release: ADP dissociates, and the NTD reopens, ready for another cycle.

Co‑chaperones such as p23, Aha1, and Cdc37 influence specific stages of this cycle, either accelerating ATP hydrolysis, stabilizing the closed state, or recruiting clients.

Client Protein Interactions

Client proteins are diverse, but common features include the presence of intrinsically disordered regions or partially folded intermediates that require assistance for proper folding. The interaction between Hsp90 and its clients is often mediated by the co‑chaperone Cdc37, which specifically binds protein kinases and directs them to Hsp90. Other co‑chaperones, such as HOP (Hsp70/Hsp90 organizing protein), shuttle clients between Hsp70 and Hsp90, ensuring a coordinated folding pathway.

Co‑Chaperones

Co‑chaperones are critical regulators of Hsp90 function. The main families include:

Regulators of ATP hydrolysis: Aha1 increases ATPase activity by binding to both NTD and MD.
Stabilizers of client complexes: p23 binds the CTD and stabilizes the closed state, delaying ADP release.
Recruitment factors: Cdc37 and Hop direct clients and other chaperones to Hsp90.
Post‑translational modifiers: CHIP (carboxyl‑terminal Hsp70‑interacting protein) promotes client ubiquitination and degradation.

The presence and stoichiometry of these co‑chaperones can dramatically alter Hsp90’s specificity and catalytic efficiency.

Regulation of Hsp90

Post-Translational Modifications

Hsp90 activity is modulated by numerous post‑translational modifications:

Phosphorylation: Serine residues in the MD can be phosphorylated by kinases such as CK2, modulating client binding.
Acetylation: Acetylation of lysine residues in the CTD reduces ATPase activity, favoring a chaperone‑repressed state.
Methylation: Methylation of arginine residues by PRMT1 influences interaction with specific co‑chaperones.
Ubiquitination: CHIP-mediated ubiquitination targets misfolded clients for proteasomal degradation, rather than refolding.

These modifications can be rapidly induced by cellular stress or signaling events, enabling a dynamic response to changing proteostasis demands.

Expression Control

Under basal conditions, Hsp90 is expressed at moderate levels. Heat shock, oxidative stress, and other proteotoxic challenges activate the heat shock factor 1 (HSF1), which upregulates the transcription of Hsp90 genes. Additionally, transcriptional co‑activators such as p300 and CBP can enhance Hsp90 expression in response to cellular growth signals. Negative feedback loops involving HSF1 phosphorylation by Hsp90 itself ensure that chaperone levels remain balanced.

Stress Response

During heat shock, the misfolding of nascent polypeptides increases the demand for chaperones. Hsp90 rapidly binds unfolded proteins, preventing aggregation, and collaborates with Hsp70 to refold or target proteins for degradation. The heat shock response also involves a coordinated upregulation of other chaperones, such as Hsp70, Hsp40, and small heat shock proteins, creating a multi‑layered proteostasis network.

Hsp90 in Cellular Processes

Protein Folding and Maturation

Hsp90’s primary role is to assist in the maturation of a subset of proteins that are particularly dependent on chaperone assistance. These include steroid hormone receptors, cell cycle regulators, and transcription factors. The ATP-dependent cycle allows Hsp90 to cycle between open and closed states, providing a platform for sequential folding steps.

Signaling Pathways

Hsp90 supports multiple signaling cascades:

Kinase pathways: Client kinases such as Raf, Akt, and CDK9 require Hsp90 for activation.
Transcription factor pathways: NF‑κB, p53, and HIF‑1α are stabilized by Hsp90, influencing transcriptional outputs.
Hormone signaling: Estrogen and androgen receptors depend on Hsp90 for proper folding and ligand binding.

Disruption of Hsp90 function can therefore have widespread effects on cell signaling and fate decisions.

Protein Quality Control

In addition to assisting proper folding, Hsp90 can participate in the degradation of irreparably damaged proteins. When clients cannot be refolded, Hsp90, often in cooperation with CHIP, targets them for ubiquitination and subsequent proteasomal degradation. This dual role ensures cellular quality control and prevents the accumulation of toxic protein aggregates.

Role in Disease

Cancer

Hsp90 is overexpressed in many tumor types, supporting the stability and activity of numerous oncogenic proteins. The chaperone’s ability to maintain the function of mutant p53, BCR‑ABL, and mutant EGFR makes it a key player in tumor survival and proliferation. Consequently, Hsp90 inhibitors are being investigated as anticancer agents.

Neurodegenerative Disorders

Protein aggregation is a hallmark of disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. Hsp90 has been implicated in the handling of amyloidogenic proteins like tau, α‑synuclein, and huntingtin. Modulation of Hsp90 activity can alter the aggregation propensity and toxicity of these proteins, suggesting therapeutic potential.

Infectious Diseases

Many pathogens, including Plasmodium falciparum, Mycobacterium tuberculosis, and viruses such as HIV and influenza, exploit host Hsp90 for their life cycles. Hsp90 assists in the maturation of viral replication proteins and the folding of parasite proteins. Inhibiting Hsp90 can therefore impair pathogen viability and replication.

Other Pathologies

Hsp90 has also been linked to cardiovascular disease, metabolic disorders, and autoimmune conditions. Its regulatory influence on signaling pathways, protein synthesis, and cellular stress responses positions it as a key modulator in diverse disease states.

Therapeutic Targeting

Inhibitors

Small‑molecule inhibitors targeting the ATP‑binding pocket of Hsp90 have been developed:

Geldanamycin and 17‑alkylamino‑17‑(2‑deoxy‑β‑D‑glucopyranosyl)-17‑(2‑carboxyethyl)amino‑17‑(4‑O‑methacryloyl‑4‑O‑methyl‑2‑(1‑hydroxyethyl)‑pyrrolidinyl)amino-17‑(4‑O‑methyl‑2‑(1‑hydroxyethyl)‑pyrrolidinyl)amino‑1‑methyl‑1H‑imidazole‑4‑yl‑2‑(4‑oxo‑4H‑pyran-3-yl)‑1‑cyclohexyl‑4‑piperidinyl (17‑AAG) bind the N‑terminal ATP pocket, locking Hsp90 in an inactive state.
Radicicol is a natural product that binds to the same site but with different structural features.
KU-55933 and other synthetic analogs have been designed to improve selectivity and pharmacokinetic properties.

These inhibitors induce the degradation of client oncoproteins by disrupting the Hsp90–client complex and facilitating ubiquitination.

Clinical Trials

Several Hsp90 inhibitors have entered clinical evaluation. 17‑AAG reached phase II trials for solid tumors, demonstrating manageable toxicity but limited efficacy as a single agent. Combination strategies with kinase inhibitors or chemotherapeutics have shown synergistic effects in preclinical models. Newer generation inhibitors with improved specificity for tumor-associated Hsp90 isoforms are currently being assessed.

Resistance Mechanisms

Resistance to Hsp90 inhibitors can arise through multiple mechanisms:

Upregulation of Hsp70 and other chaperones that compensate for Hsp90 loss.
Mutations in the ATP‑binding pocket reducing inhibitor affinity.
Activation of parallel signaling pathways that bypass Hsp90-dependent clients.

Understanding these resistance pathways is essential for designing effective therapeutic regimens.

Novel Strategies

Emerging approaches aim to modulate Hsp90’s interactions rather than its ATPase activity:

Allosteric inhibitors targeting co‑chaperone binding sites.
PROTACs (proteolysis‑targeting chimeras) that recruit E3 ligases to Hsp90‑client complexes.
Peptide‑based disruptors interfering with specific client–co‑chaperone associations.

These strategies may circumvent the limitations of ATP‑competitive inhibitors.

Structural Studies

Protein Data Bank (PDB) Entries

Multiple high‑resolution crystal structures of Hsp90 (and its complexes) have been deposited in the Protein Data Bank:

1Q2V – Hsp90 ATP‑binding domain with geldanamycin.
3JAC – Hsp90–Cdc37–kinase complex.
2O0N – Hsp90 p23 complex in the closed conformation.
4W7N – Hsp90–Aha1–ATP complex, illustrating allosteric activation.

These structures provide detailed insights into the molecular interactions and conformational changes underpinning Hsp90 function.

Key Structural Features

Essential structural motifs include:

NTD dimerization interface required for ATP binding.
MD α‑helix 12 that participates in client interaction.
CTD acidic hinge involved in p23 binding.

Crystallographic data combined with molecular dynamics simulations help elucidate the dynamic behavior of these regions.

Protein Sequences

Human Hsp90 Isoforms

The canonical sequence of human cytosolic Hsp90α (UniProt P07355) contains 732 amino acids. Hsp90β (UniProt P07356) is 732 aa as well, sharing over 90 % sequence identity. The mitochondrial isoform TRAP1 (UniProt Q9Y5X4) is 589 aa and exhibits distinct regulatory features.

Conserved Motifs

Key conserved motifs include:

NTD motif: GYI/LGGGDL involved in ATP binding.
MD motif: V/LSXDGAGP contributes to co‑chaperone recruitment.
CTD motif: GGQFGL involved in client interaction.

These motifs are highly conserved across species, reflecting the essential nature of Hsp90’s function.

Cross-Species Comparisons

Yeast Hsp90 (Hsc82 and Hsp82)

In Saccharomyces cerevisiae, Hsp90 is encoded by two genes: Hsc82 and Hsp82. Hsc82 is constitutively expressed, whereas Hsp82 is heat‑shock inducible. Yeast Hsp90 shares 73 % identity with the human cytosolic isoforms, providing a model for studying chaperone mechanics.

Plant Hsp90

Plants possess multiple Hsp90 isoforms localized to the cytosol, chloroplasts, and mitochondria. Arabidopsis thaliana Hsp90‑2 is involved in photomorphogenesis and abiotic stress tolerance. Plant Hsp90’s interaction with chloroplast protein folding machinery underscores its role in photosynthesis.

Protozoan Hsp90

Plasmodium falciparum Hsp90 is essential for parasite development. Structural studies reveal differences in the ATP‑binding pocket that allow selective targeting by antimalarial compounds. Inhibiting parasite Hsp90 can arrest erythrocytic stage development, making it a promising drug target.

Conclusion

Hsp90 is a central hub in the cellular proteostasis network, orchestrating the folding, maturation, and degradation of numerous critical proteins. Its ATP‑dependent mechanism, regulated by a diverse set of co‑chaperones and post‑translational modifications, allows it to respond rapidly to proteotoxic stress and signaling demands. Dysregulation of Hsp90 contributes to a wide range of diseases, notably cancer and neurodegeneration, rendering it an attractive therapeutic target. Continued research into its structure, client repertoire, and regulation will enhance the development of more effective drugs and deepen our understanding of cellular homeostasis.

Search

Table of Contents